Bruker (BRKR) Stock Forecast & Price Target

Compare

388 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BRKR Analyst Ratings

Moderate Buy

6 Buy

4 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Bruker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BRKR Stock 12 Month Forecast

Average Price Target

$50.63

▲(37.96%Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is $50.63 with a high forecast of $61.00 and a low forecast of $40.00. The average price target represents a 37.96% change from the last price of $36.70.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"38":"$38","79":"$79","48.25":"$48.3","58.5":"$58.5","68.75":"$68.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":61,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$61.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$50.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[38,48.25,58.5,68.75,79],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.35,41.01538461538462,42.68076923076923,44.34615384615385,46.011538461538464,47.676923076923075,49.34230769230769,51.00769230769231,52.67307692307692,54.33846153846154,56.003846153846155,57.669230769230765,59.33461538461538,{"y":61,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.35,40.21769230769231,41.08538461538462,41.95307692307692,42.82076923076923,43.68846153846154,44.55615384615385,45.423846153846156,46.291538461538465,47.159230769230774,48.02692307692308,48.894615384615385,49.762307692307694,{"y":50.63,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,39.35,39.4,39.45,39.5,39.550000000000004,39.6,39.65,39.7,39.75,39.8,39.85,39.9,39.95,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":78.76,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.28,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.15,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.06,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.63,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":59.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.09,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.35,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$61.00

Average Price Target$50.63

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$42

Hold

14.44%

Upside

Reiterated

05/15/25

Bruker's overall stock score of 68 reflects its strong financial performance and robust cash flow management, offset by high leverage and valuation risks. Technical analysis indicates a bearish trend, while the earnings call highlights significant growth alongside policy and market challenges. Positive corporate developments add strategic value, enhancing future growth prospects.

Patrick B DonnellyCiti

Citi

$50→$40

Buy

8.99%

Upside

Upgraded

05/23/25

Bruker downgraded to Neutral from Buy at CitiBruker downgraded to Neutral from Buy at Citi

Puneet SoudaLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/13/25

Bruker's Legal Settlement Boosts Investor Confidence and Supports Buy Rating

Dan LeonardUBS

UBS

$57→$45

Hold

22.62%

Upside

Reiterated

05/08/25

Bruker price target lowered to $45 from $57 at UBSBruker price target lowered to $45 from $57 at UBS

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$60

Buy

63.49%

Upside

Reiterated

05/08/25

J.P. Morgan Keeps Their Buy Rating on Bruker (BRKR)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$57→$48

Hold

30.79%

Upside

Reiterated

05/08/25

Stifel Nicolaus Remains a Hold on Bruker (BRKR)

Brandon CouillardWells Fargo

Wells Fargo

$60

Buy

63.49%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: Bruker (NASDAQ: BRKR), Qiagen (NYSE: QGEN) and Siemens Healthineers AG (Other OTC: SEMHF)

Daniel BrennanTD Cowen

TD Cowen

$45

Hold

22.62%

Upside

Reiterated

05/07/25

Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties

Michael RyskinBank of America Securities

Bank of America Securities

$76→$61

Buy

66.21%

Upside

Reiterated

05/07/25

Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges

Luke SergottBarclays

Barclays

$50→$46

Buy

25.34%

Upside

Reiterated

05/07/25

Bruker (BRKR) PT Lowered to $46 at BarclaysBarclays analyst Luke Sergott lowered the price target on Bruker (NASDAQ: BRKR) to $46.00 (from $50.00) while maintaining a Overweight rating.

Unknown AnalystCleveland Research

Not Ranked

Cleveland Research

―

Hold

―

Downgraded

04/24/25

Cleveland Research downgrades Bruker (BRKR) to NeutralCleveland Research downgraded Bruker (NASDAQ: BRKR) from Buy to Neutral.

Tycho PetersonJefferies

Jefferies

$80

Buy

117.98%

Upside

Reiterated

02/28/25

Bruker's Promising Market Position and Growth Prospects Justify Buy RatingWe highlight the the UK recently took delivery and began installation of an ultra-high field 1.2 GHz NMR system, representing the 10th EU placement. This marks the 1st GHz NMR delivery in '25 (guide assumes three). Stepping back, all focus has been on NIH noise, but we see plenty of positives (semi, microbiology, Elitech, Chemspeed), an attractive margin runway, and valuation (14x EBITDA/18x PE on '25E) that is not demanding. Reit. Buy.

Subbu NambiGuggenheim

Guggenheim

―

Buy

―

Reiterated

02/21/25

Matthew SykesGoldman Sachs

Goldman Sachs

―

Hold

―

Upgraded

12/05/24

Goldman Sachs upgrades Bruker (BRKR) to NeutralGoldman Sachs analyst Matthew Sykes upgraded Bruker (NASDAQ: BRKR) from Sell to Neutral with a price target of $60.00.

Doug SchenkelWolfe Research

Wolfe Research

―

Hold

―

Downgraded

09/30/24

Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$42

Hold

14.44%

Upside

Reiterated

05/15/25

Patrick B DonnellyCiti

Citi

$50→$40

Buy

8.99%

Upside

Upgraded

05/23/25

Bruker downgraded to Neutral from Buy at CitiBruker downgraded to Neutral from Buy at Citi

Puneet SoudaLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/13/25

Bruker's Legal Settlement Boosts Investor Confidence and Supports Buy Rating

Dan LeonardUBS

UBS

$57→$45

Hold

22.62%

Upside

Reiterated

05/08/25

Bruker price target lowered to $45 from $57 at UBSBruker price target lowered to $45 from $57 at UBS

Rachel VatnsdalJ.P. Morgan

J.P. Morgan

$60

Buy

63.49%

Upside

Reiterated

05/08/25

J.P. Morgan Keeps Their Buy Rating on Bruker (BRKR)

Daniel AriasStifel Nicolaus

Stifel Nicolaus

$57→$48

Hold

30.79%

Upside

Reiterated

05/08/25

Stifel Nicolaus Remains a Hold on Bruker (BRKR)

Brandon CouillardWells Fargo

Wells Fargo

$60

Buy

63.49%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: Bruker (NASDAQ: BRKR), Qiagen (NYSE: QGEN) and Siemens Healthineers AG (Other OTC: SEMHF)

Daniel BrennanTD Cowen

TD Cowen

$45

Hold

22.62%

Upside

Reiterated

05/07/25

Bruker Hold Rating: Balancing Optimism and Caution Amidst Uncertainties

Michael RyskinBank of America Securities

Bank of America Securities

$76→$61

Buy

66.21%

Upside

Reiterated

05/07/25

Bruker: Resilient Performance and Strategic Positioning Amidst 2025 Challenges

Luke SergottBarclays

Barclays

$50→$46

Buy

25.34%

Upside

Reiterated

05/07/25

Bruker (BRKR) PT Lowered to $46 at BarclaysBarclays analyst Luke Sergott lowered the price target on Bruker (NASDAQ: BRKR) to $46.00 (from $50.00) while maintaining a Overweight rating.

Unknown AnalystCleveland Research

Not Ranked

Cleveland Research

―

Hold

―

Downgraded

04/24/25

Cleveland Research downgrades Bruker (BRKR) to NeutralCleveland Research downgraded Bruker (NASDAQ: BRKR) from Buy to Neutral.

Tycho PetersonJefferies

Jefferies

$80

Buy

117.98%

Upside

Reiterated

02/28/25

Subbu NambiGuggenheim

Guggenheim

―

Buy

―

Reiterated

02/21/25

Matthew SykesGoldman Sachs

Goldman Sachs

―

Hold

―

Upgraded

12/05/24

Goldman Sachs upgrades Bruker (BRKR) to NeutralGoldman Sachs analyst Matthew Sykes upgraded Bruker (NASDAQ: BRKR) from Sell to Neutral with a price target of $60.00.

Doug SchenkelWolfe Research

Wolfe Research

―

Hold

―

Downgraded

09/30/24

Bruker (BRKR) was downgraded to a Hold Rating at Wolfe Research

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bruker

1 Month

xxx

Success Rate

14/31 ratings generated profit

Average Return

-0.10%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 45.16% of your transactions generating a profit, with an average return of -0.10% per trade.

3 Months

xxx

Success Rate

6/14 ratings generated profit

Average Return

-3.01%

upgraded a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -3.01% per trade.

1 Year

Brandon CouillardWells Fargo

Success Rate

16/31 ratings generated profit

Average Return

+1.61%

reiterated a buy rating 26 days ago

Copying Brandon Couillard's trades and holding each position for 1 Year would result in 51.61% of your transactions generating a profit, with an average return of +1.61% per trade.

2 Years

xxx

Success Rate

20/31 ratings generated profit

Average Return

+8.53%

reiterated a xxx

rating 26 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 64.52% of your transactions generating a profit, with an average return of +8.53% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BRKR Analyst Recommendation Trends

Rating

Jan 25

Feb 25

Mar 25

Apr 25

May 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BRKR has received 16 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. BRKR average Analyst price target in the past 3 months is 50.63.

Each month's total comprises the sum of three months' worth of ratings.

BRKR Financial Forecast

BRKR Earnings Forecast

Next quarter’s earnings estimate for BRKR is $0.44 with a range of $0.37 to $0.53. The previous quarter’s EPS was $0.47. BRKR beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 45.45% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.

BRKR Sales Forecast

Next quarter’s sales forecast for BRKR is $812.95M with a range of $805.00M to $834.30M. The previous quarter’s sales results were $801.40M. BRKR beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 57.14% of the time in the same period. In the last calendar year BRKR has Outperformed its overall industry.

BRKR Stock Forecast FAQ

What is BRKR’s average 12-month price target, according to analysts?

Based on analyst ratings, Bruker Corp’s 12-month average price target is 50.63.

What is BRKR’s upside potential, based on the analysts’ average price target?

Bruker Corp has 37.96% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BRKR a Buy, Sell or Hold?

Bruker Corp has a consensus rating of Moderate Buy which is based on 6 buy ratings, 4 hold ratings and 0 sell ratings.

What is Bruker Corp’s price target?

The average price target for Bruker Corp is 50.63. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $61.00 ,the lowest forecast is $40.00. The average price target represents 37.96% Increase from the current price of $36.7.

What do analysts say about Bruker Corp?

Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of BRKR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Bruker (BRKR) Stock Forecast & Price Target

BRKR Analyst Ratings

BRKR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bruker

BRKR Analyst Recommendation Trends

BRKR Financial Forecast

BRKR Earnings Forecast

BRKR Sales Forecast

BRKR Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts